decisionhealth Newsletters, Answer Books - 2008 Issue 12 (December)
Physician_Fee_Schedule_Rules / 161-170
Subscribe or sign in to view the full article.
Article Overview
This premium article discusses Medicare physician fee schedule policy topics from a rulemaking context, with emphasis on oncology-related demonstration reporting, drug administration valuation, clotting factor furnishing payments, and a separate supplying fee framework for certain pharmacy-dispensed drugs. It is useful for coders, billers, oncology practices, pharmacies, and compliance staff who need to understand the scope of the guidance, the organizations involved, and the general categories of coding and payment changes being addressed. The article also summarizes stakeholder comments and agency responses tied to Medicare reimbursement policy.
Why This Topic Matters
It helps readers identify whether the full rule discussion is relevant to Medicare oncology billing, drug administration coding, and other payment policy updates that can affect claims processing and practice operations.
Article Sections
-
Oncology demonstration project and patient assessment G-codes
Discusses a Medicare demonstration project for oncology practices and the reporting framework created to collect patient-reported assessment information during chemotherapy encounters.
-
Drug administration payment and coding comments
Summarizes public comments and agency responses concerning valuation, coding updates, and reporting issues for drug administration services across several specialties.
-
Blood clotting factor furnishing fee
Addresses separate payment policy for furnishing blood clotting factor, including the supporting rationale, comments received, and the final payment approach described in the rule.
-
Supplying fee
Covers a proposed separately billable supplying fee for selected pharmacy-dispensed drugs and the comments sought on implementation and related payment considerations.
What You Will Learn
- The Medicare policy areas addressed in this physician fee schedule rulemaking excerpt
- How the article frames oncology demonstration reporting within a Medicare payment context
- What broad categories of drug administration and specialty billing issues are discussed
- How separate payment topics such as clotting factor furnishing and supplying fees are presented in the rule
- Which organizations and stakeholder groups are referenced in the policy discussion
Who Should Read This
- Medical coders
- Billing specialists
- Oncology practice staff
- Pharmacy billing staff
- Compliance professionals
- Healthcare administrators
- Medicare reimbursement analysts
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com